An Observational, Non-interventional, Multi-center, Chart Review Study Conducted Among Patients Enrolled in an AZD9291 Early Access Program in Hong Kong, With Locally Advanced/Metastatic EGFR T790M Mutation-positive NSCLC and Prior Exposure to EGFR TKI Therapy.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 May 2018
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 30 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2017 Status changed from not yet recruiting to recruiting.